India Panel Calls For “Urgent” Review of Unfettered Drug-Maker FDI Policy
This article was originally published in PharmAsia News
Executive Summary
A panel of India’s Planning Commission plans to recommend that direct investments by foreign companies in the nation’s drug companies be limited to 49%.